Elevated Cyclic AMP and PDE4 Inhibition Induce Chemokine Expression in Human Monocyte-derived Macrophages

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2009 Dec 5

PMID 19959669

Citations 42

Authors

Angie L Hertz

Andrew T Bender

Kimberly C Smith

Mark Gilchrist

Paul S Amieux

Alan Aderem

Joseph A Beavo

Affiliations

Soon will be listed here.

Abstract

Macrophages are central mediators of the innate immune system that can be differentiated from monocytes upon exposure to cytokines. While increased cyclic adenosine monophosphate (cAMP) levels are known to inhibit many lipopolysaccharide-elicited macrophage inflammatory responses, the effects of elevated cAMP on monocyte/macrophage differentiation are not as well understood. We show here that during differentiation, cAMP agonists can cause a large increase in the mRNA and protein levels of several of the pro-inflammatory CXCL and CCL chemokines. The cAMP mediator-exchange protein activated by cAMP (Epac) contributes substantially to the increase in these chemokines. These chemokines are known to play an important role in the regulation of immune responses, particularly regarding the pathogenesis of asthma and chronic obstructive pulmonary disorder. We also found that a selective cAMP-degrading phosphodiesterase (PDE) 4 inhibitor can potentiate the chemokine expression elicited by low-dose forskolin or Prostaglandin E2 (PGE(2)). These data suggest that chemokine receptor antagonists administered in conjunction with a PDE4 inhibitor may improve both the efficacy and safety of PDE4-inhibitor therapy for chronic inflammatory disorders.

Citing Articles

Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects.

Lymperopoulos A, Borges J, Stoicovy R Pharmaceutics. 2024; 16(6).

PMID: 38931817 PMC: 11206770. DOI: 10.3390/pharmaceutics16060693.

Fluorogenic Probes of the Mycobacterial Membrane as Reporters of Antibiotic Action.

Wuo M, Dulberger C, Warner T, Brown R, Sturm A, Ultee E J Am Chem Soc. 2024; 146(26):17669-17678.

PMID: 38905328 PMC: 11646346. DOI: 10.1021/jacs.4c00617.

Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.

Nakamura K, Thoomukuntla B, Bena J, Cohen J, Fox R, Ontaneda D Mult Scler. 2024; 30(3):369-380.

PMID: 38286755 PMC: 11190892. DOI: 10.1177/13524585231224702.

Isoproterenol induces MD2 activation by β-AR-cAMP-PKA-ROS signalling axis in cardiomyocytes and macrophages drives inflammatory heart failure.

Qian J, Liang S, Wang Q, Xu J, Luo W, Huang W Acta Pharmacol Sin. 2023; 45(3):531-544.

PMID: 37919475 PMC: 10834947. DOI: 10.1038/s41401-023-01179-3.

Unleashing Spinal Cord Repair: The Role of cAMP-Specific PDE Inhibition in Attenuating Neuroinflammation and Boosting Regeneration after Traumatic Spinal Cord Injury.

Mussen F, Van Broeckhoven J, Hellings N, Schepers M, Vanmierlo T Int J Mol Sci. 2023; 24(9).

PMID: 37175842 PMC: 10179671. DOI: 10.3390/ijms24098135.

References

Zaccolo M, Movsesian M . cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007; 100(11):1569-78. DOI: 10.1161/CIRCRESAHA.106.144501. View

Palmqvist C, Wardlaw A, Bradding P . Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol. 2007; 151(6):725-36. PMC: 2014125. DOI: 10.1038/sj.bjp.0707263. View

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View

Fabbri L, Calverley P, Izquierdo-Alonso J, Bundschuh D, Brose M, Martinez F . Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691):695-703. DOI: 10.1016/S0140-6736(09)61252-6. View

Serezani C, Ballinger M, Aronoff D, Peters-Golden M . Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol. 2008; 39(2):127-32. PMC: 2720142. DOI: 10.1165/rcmb.2008-0091TR. View

Mosser D, Edwards J . Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008; 8(12):958-69. PMC: 2724991. DOI: 10.1038/nri2448. View

Giordano D, Magaletti D, Clark E, Beavo J . Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells. J Immunol. 2003; 171(12):6421-30. DOI: 10.4049/jimmunol.171.12.6421. View

Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux M . Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol. 2004; 173(12):7531-8. DOI: 10.4049/jimmunol.173.12.7531. View

Metcalf D . Hematopoietic cytokines. Blood. 2008; 111(2):485-91. PMC: 2200848. DOI: 10.1182/blood-2007-03-079681. View

10.

Donnelly L, Barnes P . Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci. 2006; 27(10):546-53. DOI: 10.1016/j.tips.2006.08.001. View

11.

Gilchrist M, Thorsson V, Li B, Rust A, Korb M, Roach J . Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006; 441(7090):173-8. DOI: 10.1038/nature04768. View

12.

Horuk R . Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov. 2008; 8(1):23-33. DOI: 10.1038/nrd2734. View

13.

Burke J, Pattoli M, Gregor K, Brassil P, MacMaster J, McIntyre K . BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem. 2002; 278(3):1450-6. DOI: 10.1074/jbc.M209677200. View

14.

Martorana P, Beume R, Lucattelli M, Wollin L, Lungarella G . Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med. 2005; 172(7):848-53. DOI: 10.1164/rccm.200411-1549OC. View

15.

Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A . In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol. 1997; 121(2):221-31. PMC: 1564680. DOI: 10.1038/sj.bjp.0701124. View

16.

Shepherd M, Baillie G, Stirling D, Houslay M . Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol. 2004; 142(2):339-51. PMC: 1574950. DOI: 10.1038/sj.bjp.0705770. View

17.

Montuschi P, Kharitonov S, Ciabattoni G, Barnes P . Exhaled leukotrienes and prostaglandins in COPD. Thorax. 2003; 58(7):585-8. PMC: 1746732. DOI: 10.1136/thorax.58.7.585. View

18.

Gilchrist M, Henderson Jr W, Clark A, Simmons R, Ye X, Smith K . Activating transcription factor 3 is a negative regulator of allergic pulmonary inflammation. J Exp Med. 2008; 205(10):2349-57. PMC: 2556774. DOI: 10.1084/jem.20072254. View

19.

Fu Y, Frith M, Haverty P, Weng Z . MotifViz: an analysis and visualization tool for motif discovery. Nucleic Acids Res. 2004; 32(Web Server issue):W420-3. PMC: 441564. DOI: 10.1093/nar/gkh426. View

20.

Kawasaki H, Springett G, Mochizuki N, Toki S, Nakaya M, Matsuda M . A family of cAMP-binding proteins that directly activate Rap1. Science. 1998; 282(5397):2275-9. DOI: 10.1126/science.282.5397.2275. View